Indeed, AR-negative prostate cancer cells have been shown to respond to AURKA [30], FGFR, or MAPK inhibitors [11], in line with the notion that these pathways are activated as a result of the lineage switch. The gene discussed is AURKA; the disease is prostate carcinoma.